First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome

Submitted: 10 September 2016
Accepted: 27 April 2017
Published: 3 August 2017
Abstract Views: 1234
PDF: 735
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Inflammatory myopathies as para-neoplastic phenomena were first described by Sterz in 1916. Recently, myositis specific autoantibodies were described in cancer-associated myositis. Anti-transcription intermediary factor 1 gamma (anti-TIF1γ) antibodies have been found in both young adults affected by juvenile dermatomyositis and in elderly patients with cancer-associated myositis. In this regard, we report herein the first case of anti-TIF1γ dermatomyositis secondary to a myelodysplastic syndrome.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Supporting Agencies

-
B. Palterer, Experimental and Clinical Medicine Dept., University of Florence, Florence
Resident in Allergy and Clinical Immunology
G. Vitiello, Experimental and Clinical Medicine Dept., University of Florence, Florence
Resident in Allergy and Clinical Immunology
D. Cammelli, Rheumatology Section/Immunoallergology Unit, AOU-Careggi, Florence
Head of the Reumatology Section of the Immunoallergology Unit

How to Cite

Palterer, B., Vitiello, G., & Cammelli, D. (2017). First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome. Reumatismo, 69(2), 75–77. https://doi.org/10.4081/reumatismo.2017.923